Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Restructuring Costs (2024 - 2026)

Syndax Pharmaceuticals has reported Restructuring Costs over the past 3 years, most recently at $5.1 million for Q1 2026.

  • For Q1 2026, Restructuring Costs rose 16.5% year-over-year to $5.1 million; the TTM value through Mar 2026 reached $24.0 million, down 4.91%, while the annual FY2025 figure was $23.3 million, 34.33% up from the prior year.
  • Restructuring Costs for Q1 2026 was $5.1 million at Syndax Pharmaceuticals, up from $4.8 million in the prior quarter.
  • Over five years, Restructuring Costs peaked at $11.8 million in Q2 2024 and troughed at $3.9 million in Q3 2024.
  • A 3-year average of $5.9 million and a median of $5.0 million in 2025 define the central range for Restructuring Costs.
  • On a YoY basis, Restructuring Costs climbed as much as 136.27% in 2025 and fell as far as 57.58% in 2025.
  • Year by year, Restructuring Costs stood at $5.2 million in 2024, then decreased by 8.45% to $4.8 million in 2025, then rose by 7.11% to $5.1 million in 2026.
  • Business Quant data shows Restructuring Costs for SNDX at $5.1 million in Q1 2026, $4.8 million in Q4 2025, and $9.1 million in Q3 2025.